US4871545A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical combination of nifedipine and salbutamol
Assignee: Euro Celtique SA
•
Filing: 1987-10-15
•
Granted: 1989-10-03
•
Expires: 2007-10-15
Abstract
Abstract Nifedipine is a well-known calcium antagonist, and salbutamol is a much used bronchodilator. Yet a pharmaceutical combination containing both substances is not known. Prior experience with the administration of nifedipine in combination with beta 2 -sympathomimetica did not make any combinatory effect appear probable. It was further to be feared that any combinatory effect would be accompanied by correspondingly increased side effects. The new pharmaceutical composition is nevertheless intended to provide a combination of nifedipine with a beta 2 -sympathomimeticum usable for systemic application especially in cases of asthmatic diseases. According to the invention, the pharmaceutical combination contains salbutamol besides nifedipine. The combined effect of the active substances is super-additive and synergistic. Nevertheless, no addition of side effects is experienced. The therapeutic effect of the combination corresponds approximately to the maximum achievable improvement.
Inventors
- 👤 Uwe Dethlefsen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 01:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P11/00; A61P11/08
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
39 words
A pharmaceutical preparation comprising nifedipine or a pharmaceutically acceptable salt thereof and salbutamol or a pharmaceutically acceptable salt thereof wherein the weight ratio of nifedipine or its salt to salbutamol or its salt is from about 5:1 to 1:1.
Claim 2
Dependent Claim
39 words
A pharmaceutical preparation comprising nifedipine or a pharmaceutically acceptable salt thereof and salbutamol or a pharmaceutically acceptable salt thereof wherein the weight ratio of nifedipine or its salt to salbutamol or its salt is from about 5:1 to 1:1.
Claim 3
Dependent Claim
16 words
A preparation according to claim 1, comprising nifedipine and salbutamol or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
14 words
A preparation according to claim 1, wherein the preparation is in a solid form.
Claim 5
Dependent Claim
32 words
A preparation according to claim 1, wherein the weight ratio of nifedipine or its salt to salbutamol or its salt in the preparation is between 5 to 1 and 5 to 3.
Claim 6
Dependent Claim
32 words
A preparation according to claim 4 wherein the weight ratio of nifedipine or its salt to salbutamol or its salt in the preparation is between 5 to 2 and 5 to 3.
Claim 7
Dependent Claim
27 words
A preparation according to claim 5 wherein the weight ratio of nifedipine or its salt to salbutamol or its salt in the preparation is 5 to 2.
Claim 8
Dependent Claim
20 words
A preparation according to claim 6, in unit dosage form, containing 5 mg of nifedipine and 2 mg of salbutamol.
Claim 9
Dependent Claim
21 words
A preparation according to claim 6, in unit dosage form, containing 5 mg of nifedipine and 2.4 mg of salbutamol sulphate.
Claim 10
Dependent Claim
51 words
A preparation according to claim 1, in unit dosage form, wherein the total content of nifedipine or its salt is lower than that necessary to develop significant cardiovascular effects, and the total content of salbutamol or its salt is sufficient to achieve a bronchodilating effect but insufficient to develop side effects.
Claim 11
Dependent Claim
15 words
A preparation according to claim 1 in a unit dosage form suitable for oral administration.
Claim 12
Dependent Claim
12 words
A preparation according to claim 10 in the form of a tablet.
Claim 13
Dependent Claim
22 words
A preparation according to claim 1, wherein the nifedipine or the pharmaceutically acceptable salt thereof is incorporated into a controlled release formulation.
Claim 14
Dependent Claim
26 words
A prepartion according to claim 1, comprising nifedipine having a specific surface area of less than 1 m 2 gm -1 and a water-soluble salbutamol salt.
Claim 15
Dependent Claim
21 words
A preparation according to claim 13 comprising nifedipine having a specific surface area of about 0.5 m 2 gm -1 .
Claim 16
Dependent Claim
24 words
A preparation according to claim 1, in unit dosage form, wherein the unit dosage form is coated with a pharmaceutically acceptable, light protective coating.
Claim 17
Dependent Claim
14 words
A preparation according to claim 15 wherein the coating comprises a coloured, laquer coating.
Claim 18
Independent Claim
64 words
A method for the treatment of chronic obstructive airway disease comprising administering to a patient suffering from the disease, a therapeutically active dose of a pharmaceutical preparation comprising nifedipine or a pharmaceutically acceptable salt thereof and salbutamol or a pharmaceutically acceptable salt thereof wherein the weight ratio of nifedipine or its salt to salbutamol or its salt is from about 5:1 to about 1:1.
Claim 19
Independent Claim
64 words
A method for the treatment of chronic obstructive airway disease comprising administering to a patient suffering from the disease, a therapeutically active dose of a pharmaceutical preparation comprising nifedipine or a pharmaceutically acceptable salt thereof and salbutamol or a pharmaceutically acceptable salt thereof wherein the weight ratio of nifedipine or its salt to salbutamol or its salt is from about 5:1 to about 1:1.
Claim 20
Dependent Claim
14 words
A method according to claim 17 wherein the preparation is in a solid form.
References Cited (Backward Citations)
US4337272A
Cited
US4317930A
Cited
US4582840A
Cited
US4758433A
Cited
US4716041A
Cited
US4719226A
Cited
US4652563A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-02 | 1993-04-03 | 1993-10-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-02 | 1997-04-03 | 1997-10-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-02 | 2001-04-03 | 2001-10-03 | $7700.00 | Window Closed / Lapsed |